Is CLVR or VINC more profitable?

Clever Leaves' return on equity of 0.00% beat Vincerx Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Clever Leaves N/A N/A N/A Vincerx Pharma N/A -248.33% -132.73%

Do analysts rate ADTX or CLVR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aditxt 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Clever Leaves 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, ADTX or CLVR?

Clever Leaves has higher revenue and earnings than Aditxt. Clever Leaves is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aditxt $14.34K 0.29 -$41.71M -$100.79 thousand N/A Clever Leaves $17.42M 0.00 -$17.90M -$12.36 N/A

Is ADTX or CLVR more profitable?

Clever Leaves has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Clever Leaves' return on equity of 0.00% beat Aditxt's return on equity. Company Net Margins Return on Equity Return on Assets Aditxt -360,152.50% -374.60% -105.93% Clever Leaves N/A N/A N/A

Which has stronger valuation and earnings, CLVR or SCPS?

Scopus BioPharma has lower revenue, but higher earnings than Clever Leaves. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Clever Leaves $17.42M 0.00 -$17.90M -$12.36 N/A Scopus BioPharma N/A N/A -$11.61M N/A N/A

Is CLVR or SCPS more profitable?

Company Net Margins Return on Equity Return on Assets Clever Leaves N/A N/A N/A Scopus BioPharma N/A N/A N/A

Is SMFL or CLVR more profitable?

Company Net Margins Return on Equity Return on Assets Smart for Life N/A N/A N/A Clever Leaves N/A N/A N/A

Is VRPX or CLVR more profitable?

Clever Leaves' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Virpax Pharmaceuticals N/A -1,554.34% -338.29% Clever Leaves N/A N/A N/A

Clever Leaves (CLVR) Competitors

$0.01 0.00 (0.00%)

As of 07/2/2026 10:17 AM Eastern

Compare

CLVR vs. VINC, ADTX, SCPS, SMFL, and VRPX

Should you buy Clever Leaves stock or one of its competitors? MarketBeat compares Clever Leaves with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Clever Leaves include Vincerx Pharma (VINC), Aditxt (ADTX), Scopus BioPharma (SCPS), Smart for Life (SMFL), and Virpax Pharmaceuticals (VRPX). These companies are all part of the "pharmaceutical products" industry.

How does Clever Leaves compare to Vincerx Pharma?

Clever Leaves (NASDAQ:CLVR) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

In the previous week, Clever Leaves' average media sentiment score of 0.00 equaled Vincerx Pharma'saverage media sentiment score.

Company	Overall Sentiment
Clever Leaves	Neutral
Vincerx Pharma	Neutral

Clever Leaves has higher revenue and earnings than Vincerx Pharma. Vincerx Pharma is trading at a lower price-to-earnings ratio than Clever Leaves, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clever Leaves	$17.42M	0.00	-$17.90M	-$12.36	N/A
Vincerx Pharma	N/A	N/A	-$40.16M	-$5.31	N/A

Clever Leaves' return on equity of 0.00% beat Vincerx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Clever Leaves	N/A	N/A	N/A
Vincerx Pharma	N/A	-248.33%	-132.73%

Clever Leaves has a beta of 3816.13, indicating that its share price is 381,513% more volatile than the broader market. Comparatively, Vincerx Pharma has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market.

6.9% of Clever Leaves shares are owned by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are owned by institutional investors. 8.2% of Clever Leaves shares are owned by insiders. Comparatively, 15.6% of Vincerx Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Clever Leaves beats Vincerx Pharma on 5 of the 9 factors compared between the two stocks.

How does Clever Leaves compare to Aditxt?

Aditxt (NASDAQ:ADTX) and Clever Leaves (NASDAQ:CLVR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

Aditxt has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market. Comparatively, Clever Leaves has a beta of 3816.13, meaning that its stock price is 381,513% more volatile than the broader market.

Clever Leaves has higher revenue and earnings than Aditxt. Clever Leaves is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aditxt	$14.34K	0.29	-$41.71M	-$100.79 thousand	N/A
Clever Leaves	$17.42M	0.00	-$17.90M	-$12.36	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aditxt	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Clever Leaves	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

15.5% of Aditxt shares are owned by institutional investors. Comparatively, 6.9% of Clever Leaves shares are owned by institutional investors. 0.0% of Aditxt shares are owned by company insiders. Comparatively, 8.2% of Clever Leaves shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Clever Leaves has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Clever Leaves' return on equity of 0.00% beat Aditxt's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aditxt	-360,152.50%	-374.60%	-105.93%
Clever Leaves	N/A	N/A	N/A

In the previous week, Aditxt's average media sentiment score of 0.00 equaled Clever Leaves'average media sentiment score.

Company	Overall Sentiment
Aditxt	Neutral
Clever Leaves	Neutral

Summary

Clever Leaves beats Aditxt on 8 of the 12 factors compared between the two stocks.

How does Clever Leaves compare to Scopus BioPharma?

Clever Leaves (NASDAQ:CLVR) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability.

6.9% of Clever Leaves shares are owned by institutional investors. 8.2% of Clever Leaves shares are owned by insiders. Comparatively, 5.1% of Scopus BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Clever Leaves has a beta of 3816.13, meaning that its share price is 381,513% more volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.25, meaning that its share price is 125% less volatile than the broader market.

Scopus BioPharma has lower revenue, but higher earnings than Clever Leaves.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Clever Leaves	$17.42M	0.00	-$17.90M	-$12.36	N/A
Scopus BioPharma	N/A	N/A	-$11.61M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Clever Leaves	N/A	N/A	N/A
Scopus BioPharma	N/A	N/A	N/A

In the previous week, Clever Leaves' average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company	Overall Sentiment
Clever Leaves	Neutral
Scopus BioPharma	Neutral

Summary

Clever Leaves beats Scopus BioPharma on 4 of the 5 factors compared between the two stocks.

How does Clever Leaves compare to Smart for Life?

Smart for Life (NASDAQ:SMFL) and Clever Leaves (NASDAQ:CLVR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Company	Net Margins	Return on Equity	Return on Assets
Smart for Life	N/A	N/A	N/A
Clever Leaves	N/A	N/A	N/A

Smart for Life has a beta of 15.06, indicating that its stock price is 1,406% more volatile than the broader market. Comparatively, Clever Leaves has a beta of 3816.13, indicating that its stock price is 381,513% more volatile than the broader market.

Clever Leaves has higher revenue and earnings than Smart for Life. Clever Leaves is trading at a lower price-to-earnings ratio than Smart for Life, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smart for Life	$11.11M	0.00	-$22.68M	-$14.48	N/A
Clever Leaves	$17.42M	0.00	-$17.90M	-$12.36	N/A

28.4% of Smart for Life shares are held by institutional investors. Comparatively, 6.9% of Clever Leaves shares are held by institutional investors. 31.7% of Smart for Life shares are held by insiders. Comparatively, 8.2% of Clever Leaves shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Smart for Life's average media sentiment score of 0.00 equaled Clever Leaves'average media sentiment score.

Company	Overall Sentiment
Smart for Life	Neutral
Clever Leaves	Neutral

Summary

Clever Leaves beats Smart for Life on 5 of the 8 factors compared between the two stocks.

How does Clever Leaves compare to Virpax Pharmaceuticals?

Virpax Pharmaceuticals (NASDAQ:VRPX) and Clever Leaves (NASDAQ:CLVR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

32.2% of Virpax Pharmaceuticals shares are held by institutional investors. Comparatively, 6.9% of Clever Leaves shares are held by institutional investors. 3.7% of Virpax Pharmaceuticals shares are held by insiders. Comparatively, 8.2% of Clever Leaves shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Virpax Pharmaceuticals has a beta of -16.52, suggesting that its share price is 1,752% less volatile than the broader market. Comparatively, Clever Leaves has a beta of 3816.13, suggesting that its share price is 381,513% more volatile than the broader market.

In the previous week, Virpax Pharmaceuticals' average media sentiment score of 0.00 equaled Clever Leaves'average media sentiment score.

Company	Overall Sentiment
Virpax Pharmaceuticals	Neutral
Clever Leaves	Neutral

Virpax Pharmaceuticals has higher earnings, but lower revenue than Clever Leaves. Clever Leaves is trading at a lower price-to-earnings ratio than Virpax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virpax Pharmaceuticals	N/A	N/A	-$15.19M	-$123.25	N/A
Clever Leaves	$17.42M	0.00	-$17.90M	-$12.36	N/A

Clever Leaves' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virpax Pharmaceuticals	N/A	-1,554.34%	-338.29%
Clever Leaves	N/A	N/A	N/A

Summary

Clever Leaves beats Virpax Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

Get Clever Leaves News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLVR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLVR vs. The Competition

Export

Metric	Clever Leaves	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$18K	$791.45M	$7.16B	$12.48B
Dividend Yield	N/A	4.84%	2.66%	6.52%
P/E Ratio	0.00	1.66	28.02	24.70
Price / Sales	0.00	127.11	540.37	99.49
Price / Cash	N/A	20.06	49.26	57.09
Price / Book	0.00	8.17	10.96	6.46
Net Income	-$17.90M	-$3.71M	$3.57B	$337.01M
7 Day Performance	N/A	2.59%	2.12%	1.69%
1 Month Performance	N/A	4.41%	5.25%	3.81%
1 Year Performance	N/A	49.43%	33.29%	23.90%

Clever Leaves Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLVR Clever Leaves	N/A	$0.01 flat	N/A	N/A	$18K	$17.42M	N/A	560
VINC Vincerx Pharma	N/A	$0.01 flat	N/A	-66.7%	$66K	N/A	N/A	60
ADTX Aditxt	0.6404 of 5 stars	$0.01 -76.8%	N/A	-100.0%	$30K	N/A	N/A	60	Gap Up High Trading Volume
SCPS Scopus BioPharma	N/A	$0.00 flat	N/A	N/A	$17K	N/A	N/A	9
SMFL Smart for Life	N/A	$0.00 flat	N/A	N/A	$14K	$11.11M	N/A	110

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLVR) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Clever Leaves (CLVR) Competitors

CLVR vs. VINC, ADTX, SCPS, SMFL, and VRPX

How does Clever Leaves compare to Vincerx Pharma?

Summary

How does Clever Leaves compare to Aditxt?

Summary

How does Clever Leaves compare to Scopus BioPharma?

Summary

How does Clever Leaves compare to Smart for Life?

Summary

How does Clever Leaves compare to Virpax Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLVR vs. The Competition

Clever Leaves Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Clever Leaves (CLVR) Competitors

CLVR vs. VINC, ADTX, SCPS, SMFL, and VRPX

How does Clever Leaves compare to Vincerx Pharma?

Does the media refer more to CLVR or VINC?

Which has preferable valuation and earnings, CLVR or VINC?

Is CLVR or VINC more profitable?

Which has more risk and volatility, CLVR or VINC?

Do insiders & institutionals have more ownership in CLVR or VINC?

Summary

How does Clever Leaves compare to Aditxt?

Which has more risk & volatility, ADTX or CLVR?

Which has better earnings & valuation, ADTX or CLVR?

Do analysts rate ADTX or CLVR?

Do institutionals and insiders hold more shares of ADTX or CLVR?

Is ADTX or CLVR more profitable?

Does the media prefer ADTX or CLVR?

Summary

How does Clever Leaves compare to Scopus BioPharma?

Do insiders and institutionals have more ownership in CLVR or SCPS?

Which has more volatility and risk, CLVR or SCPS?

Which has stronger valuation and earnings, CLVR or SCPS?

Is CLVR or SCPS more profitable?

Does the media refer more to CLVR or SCPS?

Summary

How does Clever Leaves compare to Smart for Life?

Is SMFL or CLVR more profitable?

Which has more volatility and risk, SMFL or CLVR?

Which has preferable earnings and valuation, SMFL or CLVR?

Do institutionals and insiders believe in SMFL or CLVR?

Does the media favor SMFL or CLVR?

Summary

How does Clever Leaves compare to Virpax Pharmaceuticals?

Do institutionals and insiders believe in VRPX or CLVR?

Which has more volatility and risk, VRPX or CLVR?

Does the media favor VRPX or CLVR?

Which has better earnings & valuation, VRPX or CLVR?

Is VRPX or CLVR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLVR vs. The Competition

Clever Leaves Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools